News | February 21, 2022
SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
The companies plan to use the proceeds to retire debt and expand operations
The companies plan to use the proceeds to retire debt and expand operations
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
In the interim, Deepak Khanna will lead Human Health International.
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
The brand has added a range of exciting new products especially formulated for oily skin.
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Subscribe To Our Newsletter & Stay Updated
